India's Aurobindo Pharma hits record high after unit launches generic version of Advair Diskus in US
31/08/2026 08:27
BUZZ-India's Aurobindo Pharma hits record high after unit launches generic version of Advair Diskus in US ** Shares of India's Aurobindo Pharma ARBN.NS rise as much as 3.5% to hit record high of 1,702 rupees
** The drugmaker says Lannett Company unit launches generic version of British pharmaceutical giant GSK's Advair Diskus in the U.S. market in 100/50 mcg and 250/50 mcg strengths
** Adds that launch marks first product from its inhalation pipeline to be commercialized in the U.S.
** Says Advair Diskus is indicated for treatment of asthma and chronic obstructive pulmonary disease
** Stock rated "buy" on average by 27 analysts; median PT is 1,770 rupees, according to LSEG-compiled data
** Stock up 43.8%, YTD
(Reporting by Payel Das in Bengaluru)
Recent news on Aurobindo Pharma
See all newsBrief: Aurobindo Pharma Gets Tax Order Confirming Total Disputed Amount 46 Million Rupees
India's Aurobindo Pharma falls after US FDA flags observation at Telangana facility
Brief: Aurobindo Pharma Says US FDA Inspected API Manufacturing Facility Of Unit Apitoria Pharma
Brief: Aurobindo Pharma Gets USFDA Final Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol
Brief: Aurobindo Pharma Says US FDA Inspected Unit-IV Of Apitoria Pharma From September 7 To September 11